Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Lymphoid 1Gastrointestinal 1Endocrine 1

Conditions

Colorectal Neoplasms 5Neoplasm Metastasis 4Sarcoma 3Rectal Neoplasms 3Colonic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Pancreatic Neoplasms 2Lymphoma 2Ovarian Neoplasms 1Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Insulin-Like Growth Factor I, Resistance To 1Hodgkin Disease 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoid Tumor 1Adenocarcinoma 1

Interventions

Octreotide 5Everolimus 5pasireotide 3lanreotide 2Bevacizumab 2surufatinib 1pembrolizumab 1ganitumab 1fosbretabulin 1epothilone B 1conatumumab 1cixutumumab 1azaspirane 1arginyllysine 1TKM-080301 1Sunitinib 1Rose Bengal 1Random Allocation 1Quality of Life 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Immunotherapy 1Drug Therapy 1CX 3543 1Biological Therapy 1Biological Factors 12-Methoxyestradiol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoid Tumor × conatumumab × Clear all
NCT01327612 2021-02-21

Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)

Amgen

Phase 2 Completed
12 enrolled 21 charts
EndocrineGastrointestinalLymphoidSarcomaThoracic

Carcinoid Tumor, Carcinoma, Non-Small-Cell Lung, Lymphoma, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡